{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9%25+w%2Fv+NaCL+Saline&page=2",
    "query": {
      "intervention": "0.9% w/v NaCL Saline",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 37,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9%25+w%2Fv+NaCL+Saline&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9%25+w%2Fv+NaCL+Saline&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T12:47:30.067Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01188564",
      "title": "Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hereditary Angioedema"
      ],
      "interventions": [
        {
          "name": "rhC1INH",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Saline)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharming Technologies B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2011-01",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2015-08-07",
      "last_synced_at": "2026-10-10T12:47:30.067Z",
      "location_count": 15,
      "location_summary": "Scottsdale, Arizona • Granada Hills, California • Los Angeles, California + 12 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Granada Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01188564"
    },
    {
      "nct_id": "NCT04584684",
      "title": "Mouth Rinses for Inactivation of COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Covid19",
        "Coronavirus Infection",
        "SARS-CoV-2 Infection"
      ],
      "interventions": [
        {
          "name": "0.9% w/v NaCL Saline",
          "type": "OTHER"
        },
        {
          "name": "1.5% w/v Hydrogen Peroxide",
          "type": "DRUG"
        },
        {
          "name": "0.12% Chlorohexidine Gluconate",
          "type": "DRUG"
        },
        {
          "name": "27% Ethanol plus essential oils",
          "type": "DRUG"
        },
        {
          "name": "0.5% w/v Povidone-iodide",
          "type": "DRUG"
        },
        {
          "name": "0.075% Cetylpyridinium Chloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 128,
      "start_date": "2020-12-18",
      "completion_date": "2021-10-21",
      "has_results": true,
      "last_update_posted_date": "2024-03-25",
      "last_synced_at": "2026-10-10T12:47:30.067Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04584684"
    },
    {
      "nct_id": "NCT06022224",
      "title": "A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "hAd5-S-Fusion+N-ETSD",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (0.9% (w/v) saline)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "16 Years to 80 Years"
      },
      "enrollment_count": 35,
      "start_date": "2020-12-09",
      "completion_date": "2023-07-19",
      "has_results": true,
      "last_update_posted_date": "2024-06-07",
      "last_synced_at": "2026-10-10T12:47:30.067Z",
      "location_count": 1,
      "location_summary": "Newport Beach, California",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06022224"
    },
    {
      "nct_id": "NCT02963831",
      "title": "A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Ovarian Cancer",
        "Appendiceal Cancer"
      ],
      "interventions": [
        {
          "name": "ONCOS-102",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Ludwig Institute for Cancer Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2017-09-07",
      "completion_date": "2022-06-25",
      "has_results": true,
      "last_update_posted_date": "2022-12-22",
      "last_synced_at": "2026-10-10T12:47:30.067Z",
      "location_count": 6,
      "location_summary": "San Diego, California • Miami, Florida • Buffalo, New York + 3 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Toledo",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02963831"
    },
    {
      "nct_id": "NCT01915212",
      "title": "Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "HSV529",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 69,
      "start_date": "2013-09-26",
      "completion_date": "2017-03-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-10-10T12:47:30.067Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01915212"
    },
    {
      "nct_id": "NCT03041025",
      "title": "Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Scleroderma, Systemic"
      ],
      "interventions": [
        {
          "name": "GSK2330811",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2017-06-05",
      "completion_date": "2020-07-07",
      "has_results": true,
      "last_update_posted_date": "2021-05-24",
      "last_synced_at": "2026-10-10T12:47:30.067Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Stanford, California • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03041025"
    },
    {
      "nct_id": "NCT03461211",
      "title": "Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thyroid Eye Disease"
      ],
      "interventions": [
        {
          "name": "Teprotumumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 51,
      "start_date": "2018-04-16",
      "completion_date": "2021-02-17",
      "has_results": true,
      "last_update_posted_date": "2024-06-28",
      "last_synced_at": "2026-10-10T12:47:30.067Z",
      "location_count": 8,
      "location_summary": "Beverly Hills, California • Los Angeles, California • Miami, Florida + 5 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03461211"
    },
    {
      "nct_id": "NCT01771471",
      "title": "A Study Comparing the Safety and Effectiveness of Cartilage Cell Injected Into the Lumbar Disc as Compared to a Placebo",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Degenerative Disc Disease"
      ],
      "interventions": [
        {
          "name": "NuQu",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "ISTO Technologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2012-11",
      "completion_date": "2020-09",
      "has_results": false,
      "last_update_posted_date": "2017-08-31",
      "last_synced_at": "2026-10-10T12:47:30.067Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Santa Monica, California + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Macon",
          "state": "Georgia"
        },
        {
          "city": "Newton",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01771471"
    },
    {
      "nct_id": "NCT01396187",
      "title": "Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "PF-05231023",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "30 Years to 70 Years"
      },
      "enrollment_count": 50,
      "start_date": "2011-07",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2015-01-12",
      "last_synced_at": "2026-10-10T12:47:30.067Z",
      "location_count": 5,
      "location_summary": "Chula Vista, California • Miami, Florida • South Miami, Florida + 2 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01396187"
    },
    {
      "nct_id": "NCT02799472",
      "title": "Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Arthritis, Rheumatoid"
      ],
      "interventions": [
        {
          "name": "GSK3196165",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "MTX",
          "type": "DRUG"
        },
        {
          "name": "Folic (or folinic) acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2016-06-15",
      "completion_date": "2017-10-30",
      "has_results": true,
      "last_update_posted_date": "2021-01-11",
      "last_synced_at": "2026-10-10T12:47:30.067Z",
      "location_count": 8,
      "location_summary": "El Cajon, California • Fort Lauderdale, Florida • Miami, Florida + 5 more",
      "locations": [
        {
          "city": "El Cajon",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Pinellas Park",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02799472"
    }
  ]
}